Concerns with beta2-agonists in pediatric asthma - a clinical perspective

被引：13

作者：

Kersten, Elin T. G. ^{[1
]}

Koppelman, Gerard H. ^{[1
]}

Thio, Bernard J. ^{[2
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol,GRIAC Res, POB 30-001, NL-9700 RB Groningen, Netherlands

[2] Medisch Spectrum Twente, Dept Pediat, NL-7512 KZ Enschede, Netherlands

来源：

PAEDIATRIC RESPIRATORY REVIEWS | 2017年 / 21卷

关键词：

beta; 2-agonists; Tolerance; Asthma; Genetic polymorphisms; LONG-ACTING BETA(2)-AGONISTS; AGE-RELATED-CHANGES; BETA-AGONISTS; UNITED-STATES; SALMETEROL; FORMOTEROL; CHILDREN; MORTALITY; THERAPY; BETA(2)-ADRENOCEPTOR;

D O I：

10.1016/j.prrv.2016.05.006

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Beta2-adrenoreceptor agonists (beta 2-agonists) are extensively used in the treatment of childhood asthma. However, there have been concerns regarding their adverse effects and safety. In 2005, the FDA commissioned a "Black Box Warning" communicating the potential for an increased risk for serious asthma exacerbations or asthma related deaths, with the regular use of LABAs. In a meta-analysis of controlled clinical trials, the incidence of severe adverse events appeared to be highest in the 4-11 year age group. Several mechanisms have been proposed regarding the risk of regular use of beta 2-agonists, such as masking patients' perception of worsening asthma, desensitization and downregulation of the beta 2-adrenoreceptor, pro-inflammatory effects of beta 2-agonists, pharmacogenetic effects of beta 2-adrenoreceptor polymorphisms and age related differences in pathophysiology of asthma. In this paper, we review beta 2-receptor pharmacology, discuss the concerns regarding treatment with beta 2-agonists in childhood asthma, and provide suggestions for clinical pediatric practice in the light of current literature. (C) 2016 Elsevier Ltd. All rights reserved.

引用

页码：80 / 85

页数：6

共 50 条

[21] Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Chauhan, Bhupendrasinh F.
Chartrand, Caroline
Chroinin, Muireann Ni
Milan, Stephen J.
Ducharme, Francine M.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (11):
[22] Beta2-agonists for exercise-induced asthma (vol 19, pg 355, 2014)
Smith, W. G.
PAEDIATRICS & CHILD HEALTH, 2015, 20 (08) : 466 - 466
[23] Why isn't there more controversy on long-acting beta2-agonists in asthma?
Boussageon, R.
REVUE DES MALADIES RESPIRATOIRES, 2011, 28 (08) : 1079 - 1080
[24] Beta2-Agonists and Perinatal Outcomes: A Review of the Evidence
Eltonsy, Sherif
Kettani, Fatima-Zohra
Blais, Lucie
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S48 - S49
[25] Desloratadine reduces the use of inhaled beta2-agonists and improves asthma symptoms in patients with seasonal allergic rhinitis and asthma
Corren, J
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (02) : S163 - S163
[26] Short-acting beta2-agonists ( SABA) usage patterns from asthma control level perspective. Results from an asthma patients survey
Bumbacea, R. S.
Bumbacea, D.
Panaitescu, C.
ALLERGY, 2020, 75 : 402 - 403
[27] The safety of regular long-acting beta2-agonists in children with asthma: an overview of Cochrane reviews
Cates, Chris
PAEDIATRIC RESPIRATORY REVIEWS, 2013, 14 (01) : 25 - 26
[28] Are beta2-agonists responsible for increased mortality in heart failure?
Bermingham, Margaret
O'Callaghan, Eleanor
Dawkins, Ian
Miwa, Saki
Samsudin, Shazzarina
McDonald, Kenneth
Ledwidge, Mark
EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (08) : 885 - 891
[29] Beta 2-adrenoreceptor agonists: a new perspective in the treatment of asthma?
Quadrelli, SA
Roncoroni, AJ
Pinna, DM
MEDICINA-BUENOS AIRES, 1999, 59 (03) : 293 - 299
[30] Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children
Griffiths, Benedict
Ducharme, Francine M.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (08):

← 1 2 3 4 5 →